March 21, 2025 FDA Approves Guselkumab for Crohn’s Disease The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab. Conexiant
March 24, 2025 Longer Breastfeeding Duration Linked to Fewer Developmental Delays in Large Study Conexiant